RBC Capital Maintains Outperform on Nurix Therapeutics, Lowers Price Target to $22
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Gregory Renza has maintained an Outperform rating on Nurix Therapeutics (NASDAQ:NRIX) but lowered the price target from $24 to $22.

February 16, 2024 | 5:38 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
RBC Capital maintains an Outperform rating on Nurix Therapeutics but lowers the price target from $24 to $22.
While the reduction in price target from $24 to $22 by RBC Capital might initially seem negative, the maintenance of an Outperform rating by analyst Gregory Renza suggests a continued positive outlook on Nurix Therapeutics. The adjustment in price target reflects a recalibration of expectations rather than a fundamental shift in the company's prospects. Investors might see this as a nuanced adjustment rather than a cause for concern.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100